Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Mutation Analysis of the RAD51C and RAD51D Genes in High-Risk Ovarian Cancer Patients and Families from the Czech Republic

M. Janatova, J. Soukupova, J. Stribrna, P. Kleiblova, M. Vocka, P. Boudova, Z. Kleibl, P. Pohlreich,

. 2015 ; 10 (6) : e0127711. [pub] 20150609

Language English Country United States

Document type Journal Article, Research Support, Non-U.S. Gov't

Grant support
NT13343 MZ0 CEP Register

Recent studies have conferred that the RAD51C and RAD51D genes, which code for the essential proteins involved in homologous recombination, are ovarian cancer (OC) susceptibility genes that may explain genetic risks in high-risk patients. We performed a mutation analysis in 171 high-risk BRCA1 and BRCA2 negative OC patients, to evaluate the frequency of hereditary RAD51C and RAD51D variants in Czech population. The analysis involved direct sequencing, high resolution melting and multiple ligation-dependent probe analysis. We identified two (1.2%) and three (1.8%) inactivating germline mutations in both respective genes, two of which (c.379_380insG, p.P127Rfs*28 in RAD51C and c.879delG, p.C294Vfs*16 in RAD51D) were novel. Interestingly, an indicative family cancer history was not present in four carriers. Moreover, the ages at the OC diagnoses in identified mutation carriers were substantially lower than those reported in previous studies (four carriers were younger than 45 years). Further, we also described rare missense variants, two in RAD51C and one in RAD51D whose clinical significance needs to be verified. Truncating mutations and rare missense variants ascertained in OC patients were not detected in 1226 control samples. Although the cumulative frequency of RAD51C and RAD51D truncating mutations in our patients was lower than that of the BRCA1 and BRCA2 genes, it may explain OC susceptibility in approximately 3% of high-risk OC patients. Therefore, an RAD51C and RAD51D analysis should be implemented into the comprehensive multi-gene testing for high-risk OC patients, including early-onset OC patients without a family cancer history.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc16020699
003      
CZ-PrNML
005      
20191014125152.0
007      
ta
008      
160722s2015 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1371/journal.pone.0127711 $2 doi
024    7_
$a 10.1371/journal.pone.0127711 $2 doi
035    __
$a (PubMed)26057125
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Janatová, Markéta $u Institute of Biochemistry and Experimental Oncology, First Faculty of Medicine, Charles University in Prague, Prague, Czech Republic. $7 stk2008428924
245    10
$a Mutation Analysis of the RAD51C and RAD51D Genes in High-Risk Ovarian Cancer Patients and Families from the Czech Republic / $c M. Janatova, J. Soukupova, J. Stribrna, P. Kleiblova, M. Vocka, P. Boudova, Z. Kleibl, P. Pohlreich,
520    9_
$a Recent studies have conferred that the RAD51C and RAD51D genes, which code for the essential proteins involved in homologous recombination, are ovarian cancer (OC) susceptibility genes that may explain genetic risks in high-risk patients. We performed a mutation analysis in 171 high-risk BRCA1 and BRCA2 negative OC patients, to evaluate the frequency of hereditary RAD51C and RAD51D variants in Czech population. The analysis involved direct sequencing, high resolution melting and multiple ligation-dependent probe analysis. We identified two (1.2%) and three (1.8%) inactivating germline mutations in both respective genes, two of which (c.379_380insG, p.P127Rfs*28 in RAD51C and c.879delG, p.C294Vfs*16 in RAD51D) were novel. Interestingly, an indicative family cancer history was not present in four carriers. Moreover, the ages at the OC diagnoses in identified mutation carriers were substantially lower than those reported in previous studies (four carriers were younger than 45 years). Further, we also described rare missense variants, two in RAD51C and one in RAD51D whose clinical significance needs to be verified. Truncating mutations and rare missense variants ascertained in OC patients were not detected in 1226 control samples. Although the cumulative frequency of RAD51C and RAD51D truncating mutations in our patients was lower than that of the BRCA1 and BRCA2 genes, it may explain OC susceptibility in approximately 3% of high-risk OC patients. Therefore, an RAD51C and RAD51D analysis should be implemented into the comprehensive multi-gene testing for high-risk OC patients, including early-onset OC patients without a family cancer history.
650    _2
$a protein BRCA1 $x genetika $7 D019313
650    _2
$a protein BRCA2 $x genetika $7 D024682
650    _2
$a sekvence nukleotidů $7 D001483
650    _2
$a mutační analýza DNA $7 D004252
650    _2
$a komplementární DNA $x genetika $7 D018076
650    _2
$a DNA vazebné proteiny $x genetika $7 D004268
650    _2
$a exony $x genetika $7 D005091
650    _2
$a rodina $7 D005190
650    _2
$a ženské pohlaví $7 D005260
650    12
$a geny nádorové $7 D052138
650    12
$a genetická predispozice k nemoci $7 D020022
650    _2
$a lidé $7 D006801
650    _2
$a introny $x genetika $7 D007438
650    _2
$a molekulární sekvence - údaje $7 D008969
650    _2
$a nádory vaječníků $x genetika $7 D010051
650    _2
$a rizikové faktory $7 D012307
651    _2
$a Česká republika $7 D018153
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Soukupová, Jana $u Institute of Biochemistry and Experimental Oncology, First Faculty of Medicine, Charles University in Prague, Prague, Czech Republic. $7 xx0239539
700    1_
$a Stribrna, Jana $u Institute of Biochemistry and Experimental Oncology, First Faculty of Medicine, Charles University in Prague, Prague, Czech Republic.
700    1_
$a Kleiblová, Petra $u Institute of Biochemistry and Experimental Oncology, First Faculty of Medicine, Charles University in Prague, Prague, Czech Republic; Institute of Biology and Medical Genetics, First Faculty of Medicine, Charles University in Prague and General University Hospital in Prague, Prague, Czech Republic. $7 xx0125463
700    1_
$a Vočka, Michal $u Department of Oncology, First Faculty of Medicine, Charles University in Prague, General University Hospital in Prague and Military University Hospital Prague, Prague, Czech Republic. $7 xx0181880
700    1_
$a Zemánková, Petra $u Institute of Biochemistry and Experimental Oncology, First Faculty of Medicine, Charles University in Prague, Prague, Czech Republic. $7 xx0239540
700    1_
$a Kleibl, Zdeněk, $u Institute of Biochemistry and Experimental Oncology, First Faculty of Medicine, Charles University in Prague, Prague, Czech Republic. $d 1969- $7 jo2003183974
700    1_
$a Pohlreich, Petr, $u Institute of Biochemistry and Experimental Oncology, First Faculty of Medicine, Charles University in Prague, Prague, Czech Republic. $d 1947-2015 $7 jn20000710479
773    0_
$w MED00180950 $t PloS one $x 1932-6203 $g Roč. 10, č. 6 (2015), s. e0127711
856    41
$u https://pubmed.ncbi.nlm.nih.gov/26057125 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20160722 $b ABA008
991    __
$a 20191014125616 $b ABA008
999    __
$a ok $b bmc $g 1155369 $s 945227
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2015 $b 10 $c 6 $d e0127711 $e 20150609 $i 1932-6203 $m PLoS One $n PLoS One $x MED00180950
GRA    __
$a NT13343 $p MZ0
LZP    __
$a Pubmed-20160722

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...